We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Read MoreHide Full Article
Shares of Aprea Therapeutics (APRE - Free Report) were up 12% on Jan 11 after management announced that it dosed the first patient in a phase I/IIa study with its lead pipeline candidate ATRN-119, for the treatment of advanced solid tumors.
The phase I/IIa study will evaluate ATRN-119, Aprea’s small molecule ATR inhibitor, as a potential treatment of cancers with DNA damage response (DDR) mutation. The phase I portion of this study will assess the tolerability, pharmacokinetics, recommended phase II dose and analysis of patient biomarkers, while the phase IIa portion will further evaluate the tolerability and efficacy of ATRN-119.
Aprea plans to share preliminary data from the above study throughout 2023.
Shares of Aprea Therapeutics have plunged 80.2% in the past year compared with the industry’s 13.8% fall.
Image Source: Zacks Investment Research
The initiation of the clinical study for ATRN-119 is based on pre-clinical studies which showed potent anti-proliferative activity of ATRN-119 against various cancer indications and inhibited tumor growth. Treatment with ATRN-119 has also shown the potential to have lower hematological toxicity when compared to other ATR inhibitors.
Apart from ATRN-119, Aprea has no other pipeline candidate in clinical development. Management intends to advance ATRN-1051, a novel WEE1 inhibitor, to clinical development and plans to submit an investigational new drug (IND) application later this year in the fourth quarter.
In the past 60 days, estimates for Allogene’s 2022 loss per share have narrowed from $2.39 to $2.38. In the same period, the loss per share estimate for 2023 has narrowed from $2.84 to $2.82. Shares of Allogene have declined 45.2% in the past year.
Earnings of Allogene beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
In the past 60 days, estimates for Novo Nordisk’s 2022 earnings per share have risen from $3.25 to $3.38. During the same period, the earnings estimates per share for 2023 have risen from $3.98 to $4.15. Shares of Novo Nordisk have risen 33.2% in the past year.
Earnings of Novo Nordisk beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 3.09%, on average. In the last reported quarter, Novo Nordisk’searnings beat estimates by 2.38%.
In the past 60 days, estimates for Sanofi’s 2022 earnings per share have risen from $4.16 to $4.31. During the same period, the earnings estimates per share for 2023 have risen from $4.29 to $4.35. Shares of Sanofi have declined 3.9% in the past year.
Earnings of Sanofi beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.50%, on average. In the last reported quarter, Sanofi’s earnings beat estimates by 9.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Shares of Aprea Therapeutics (APRE - Free Report) were up 12% on Jan 11 after management announced that it dosed the first patient in a phase I/IIa study with its lead pipeline candidate ATRN-119, for the treatment of advanced solid tumors.
The phase I/IIa study will evaluate ATRN-119, Aprea’s small molecule ATR inhibitor, as a potential treatment of cancers with DNA damage response (DDR) mutation. The phase I portion of this study will assess the tolerability, pharmacokinetics, recommended phase II dose and analysis of patient biomarkers, while the phase IIa portion will further evaluate the tolerability and efficacy of ATRN-119.
Aprea plans to share preliminary data from the above study throughout 2023.
Shares of Aprea Therapeutics have plunged 80.2% in the past year compared with the industry’s 13.8% fall.
Image Source: Zacks Investment Research
The initiation of the clinical study for ATRN-119 is based on pre-clinical studies which showed potent anti-proliferative activity of ATRN-119 against various cancer indications and inhibited tumor growth. Treatment with ATRN-119 has also shown the potential to have lower hematological toxicity when compared to other ATR inhibitors.
Apart from ATRN-119, Aprea has no other pipeline candidate in clinical development. Management intends to advance ATRN-1051, a novel WEE1 inhibitor, to clinical development and plans to submit an investigational new drug (IND) application later this year in the fourth quarter.
Aprea Therapeutics, Inc. Price
Aprea Therapeutics, Inc. price | Aprea Therapeutics, Inc. Quote
Zacks Rank & Stock to Consider
Aprea currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Allogene (ALLO - Free Report) , Novo Nordisk (NVO - Free Report) and Sanofi (SNY - Free Report) , each of which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Allogene’s 2022 loss per share have narrowed from $2.39 to $2.38. In the same period, the loss per share estimate for 2023 has narrowed from $2.84 to $2.82. Shares of Allogene have declined 45.2% in the past year.
Earnings of Allogene beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.44%, on average. In the last reported quarter, Allogene’s earnings beat estimates by 6.45%.
In the past 60 days, estimates for Novo Nordisk’s 2022 earnings per share have risen from $3.25 to $3.38. During the same period, the earnings estimates per share for 2023 have risen from $3.98 to $4.15. Shares of Novo Nordisk have risen 33.2% in the past year.
Earnings of Novo Nordisk beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 3.09%, on average. In the last reported quarter, Novo Nordisk’searnings beat estimates by 2.38%.
In the past 60 days, estimates for Sanofi’s 2022 earnings per share have risen from $4.16 to $4.31. During the same period, the earnings estimates per share for 2023 have risen from $4.29 to $4.35. Shares of Sanofi have declined 3.9% in the past year.
Earnings of Sanofi beat estimates in each of the last four quarters, witnessing an earnings surprise of 9.50%, on average. In the last reported quarter, Sanofi’s earnings beat estimates by 9.85%.